No. | Age | Gender | Route of Infection | HCV RNA | ALT | AST | TBil | PLT | Cirrhosis | FIB-4 | APRI | Treatment | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Strategy | Actual Duration | ||||||||||||
1 | 48 | M | Unknown | 4.34 | 73 | 87 | 18.4 | 132 | no | 3.70 | 1.65 | SOF + DCV | 12 |
2 | 50 | M | Travenous drug abuse | 6.30 | 46 | 70 | 16.2 | 117 | no | 4.41 | 1.50 | SOF + DCV | 12 |
3 | 25 | F | Travenous drug abuse | 6.54 | 52 | 84 | 17.7 | 152 | no | 1.92 | 1.38 | SOF + DCV | 12 |
4 | 73 | M | Blood products | 4.16 | 155 | 217 | 29.5 | 32 | yes | 39.76 | 16.95 | SOF + DCV | 24 |
5 | 35 | M | Travenous drug abuse | 6.85 | 24.6 | 47.7 | 28.2 | 34 | yes | 9.90 | 3.51 | SOF + DCV + RB | 12 |
6 | 37 | M | Unknown | 7.35 | 72.1 | 115.8 | 29 | 182 | yes | 2.77 | 1.59 | SOF + DCV + RB | 12 |
7 | 36 | M | Travenous drug abuse | 6.98 | 331 | 221 | 29.1 | 82 | yes | 5.33 | 6.74 | SOF + DCV | 24 |
8 | 41 | M | Travenous drug abuse | 6.53 | 124 | 144 | 17.3 | 82 | yes | 6.47 | 4.399 | SOF + DCV | 12 |
9 | 43 | F | Travenous drug abuse | 6.00 | 100 | 100 | 13.2 | 34 | yes | 12.65 | 7.35 | SOF + DCV | 12 |
10 | 48 | F | Blood products | 7.06 | 81 | 122.8 | 12.6 | 59 | no | 11.10 | 5.20 | SOF + DCV | 12 |